ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements
NCLT admitted CIRP against Evoq Remedies Ltd for a Rs.1.95 Crore operational debt. An IRP has been appointed, and a moratorium is in effect.
An operational creditor has filed an insolvency petition against Evoq Remedies under IBC Section 9. The NCLT admission initiates the CIRP process, posing significant risk for shareholders.
Evoq Remedies Limited reported audited financial results for the year ended March 31, 2026. The auditor issued a qualified opinion citing material uncertainty regarding going concern.
Evoq Remedies Ltd reported a net loss of ₹0.3 Cr for H2 FY26.
Evoq Remedies Limited reported annual revenue of ₹26.76 Crore for FY2026. The board also appointed M/s. Jay Pandya & Associates as secretarial auditors for FY2025-26.
Evoq Remedies rescheduled its board meeting from May 27 to May 30, 2026. Directors will consider audited financial results for the fiscal year ended March 31.
Evoq Remedies rescheduled its Board Meeting from May 14 to May 27, 2026. Directors will consider audited financial results for the fiscal year ended March 2026.
Evoq Remedies Limited has scheduled a Board of Directors meeting for May 14, 2026. The board will primarily consider and approve the audited financial results for the half-year and full year ended March 31, 2026.
Evoq Remedies Limited (BSE: 543500) has submitted its initial disclosure confirming it does not meet the SEBI criteria for 'Large Corporate' classification for the financial year. The company reported nil outstanding borrowings as of March 31, 2026. This regulatory filing ensures compliance with debt sourcing framework requirements.